← GIP/GLP-1 & amylin agonists × body weight & composition

SynthesisFrontiers in endocrinology2025

Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis.

Qiru Tian et al.PubMed ↗Full text ↗Publisher ↗

  • Tirzepatidecuts both waysLower weight reduction.Randomised, small.
  • Tirzepatide at 5 mglooks good hereLower weight loss.Weak evidence: one subgroup.
  • Tirzepatide at 10 mglooks good hereLower weight loss.Weak evidence: one subgroup.
  • Tirzepatide at 15 mglooks good hereLower weight loss.Weak evidence: one subgroup.

What the trial testedrandomised · 2025

Randomised vs placebo

Probably lowered weight reduction

−10.4kg−10.8 to −9.99

tirzepatide vs placebo

As reported

difference −10.39 kg, 95% CI −10.8 to −9.99

One subgroup

May have lowered weight loss in patients with type 2 diabetes

−6.17kg−7.16 to −5.17

tirzepatide at 5 mg vs placebo, in patients with type 2 diabetes

As reported

difference −6.17 kg, 95% CI −7.16 to −5.17

One subgroup

May have lowered weight loss in non-diabetic participants

−12.1kg−13.5 to −10.7

tirzepatide at 5 mg vs placebo, in non-diabetic participants

As reported

difference −12.10 kg, 95% CI −13.5 to −10.7

One subgroup

May have lowered weight loss in non-diabetic participants

−15.9kg−17.3 to −14.6

tirzepatide at 10 mg vs placebo, in non-diabetic participants

As reported

difference −15.94 kg, 95% CI −17.3 to −14.6

+6 more in the walkthrough ↓

Who was studied, and how

people with obesity, in this paper

The trial randomly assignedassigned by chance

tirzepatide
placebo

Probably lowered weight reduction−10.4

Reported higher achieving clinically meaningful weight loss ≥ 5%, no range given11×

randomised

Among patients with type 2 diabetes, the trial randomly assignedassigned by chance

tirzepatide at 5 mg
placebo

May have lowered weight loss−6.17

randomised · one subgroup

the abstract, start to end

… induced a mean weight reduction of -10.39 kg versus placebo (95% CI: …

… that patients with type 2 diabetes lost -6.17 kg (95% CI: -7.16 to -5.17; p < …

… experienced greater absolute losses of -12.10 kg (95% CI: -13.47 to -10.72; p < 0.00001), -15.94 kg (95% CI: -17.25 to -14.62; p < 0.00001), and -17.86 kg (95% CI: -19.19 to -16.54; p …

… meaningful weight loss: ≥ 5% (OR=11.32; p < 0.0001), ≥ 10% (OR=14.77; p < 0.0001), and ≥ 15% (OR=18.07; p < 0.0001.

… with tirzepatide than placebo (OR=1.34; p < 0.0001), largely driven by …

… effects increased at higher doses (OR=2.31; p < 0.0001).

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Weight reductiontirzepatide vs placebo
−10.39−10.8 to −9.99
Weight losstirzepatide at 5 mg vs placebo, in patients with type 2 diabetes
−6.17−7.16 to −5.17
Weight losstirzepatide at 5 mg vs placebo, in non-diabetic participants
−12.10−13.5 to −10.7
Weight losstirzepatide at 10 mg vs placebo, in non-diabetic participants
−15.94−17.3 to −14.6
Weight losstirzepatide at 15 mg vs placebo, in non-diabetic participants
−17.86−19.2 to −16.5
Achieving clinically meaningful weight loss ≥ 5%tirzepatide vs placebo
OR 11.32
Achieving clinically meaningful weight loss ≥ 10%tirzepatide vs placebo
OR 14.77
Achieving clinically meaningful weight loss ≥ 15%tirzepatide vs placebo
OR 18.07
Adverse eventstirzepatide vs placebo
OR 1.34
Discontinuations due to side effectstirzepatide at higher doses vs tirzepatide at lower doses (implied reference)
OR 2.31
GIP/GLP-1 & amylin agonistsBody weight & compositionAdverse events & safety

GIP/GLP-1 & amylin agonists × body weight & compositionhelps?replicated

unlikelylikely
1.00not counted

GIP/GLP-1 & amylin agonists × adverse events & safetyharms?mixed

unlikelylikely
0.00not counted
← favours treatmentfavours comparator →
more certainless certain
1 / 6

6 papers cite it

2025
2026
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 40747302